1. Canada Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Cotinga Pharmaceuticals Inc.

Cotinga Pharmaceuticals Inc.

COTQF
Cotinga Pharmaceuticals Inc.US flagOther OTC
0.00
USD
- -
- -
2,199.00Market Cap
2007 Y
2008 Y
2009 Y
2010 Y
2011 Y
2012 Y
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
TTM
Revenue per Share
- -
0.01
0.01
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
-0.48
-0.46
-0.84
-0.76
-0.39
-0.41
-0.35
-0.34
-0.35
-0.39
-0.42
-0.31
-0.12
-0.12
Free Cash Flow per Basic Share
-0.39
-0.54
-0.61
-0.56
-0.37
-0.33
-0.28
-0.22
-0.3
-0.3
-0.31
-0.25
-0.08
-0.02
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-0.79
-1.03
-1.76
-2.51
-2.7
-2.57
-2.52
-2.46
-2.37
-2.41
-2.49
-0.56
-0.48
-0.55
Tangible Book Value per Share
0.74
1.38
0.75
0.38
0.4
0.26
0.01
0.01
0.02
0.2
-0.05
-0.16
-0.14
-0.21
Basic Weighted Avg Shares
3
4
5
5
5
6
8
9
11
13
15
16
22
22
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
-60,457.72
-6,803.01
-8,309.03
- -
- -
- -
-8,607.6
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
1
- -
- -
1
1
1
- -
- -
- -
- -
- -
Net Income, GAAP
-1
-2
-4
-4
-2
-3
-3
-3
-4
-5
-6
-5
-3
-3
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-57,199.32
-6,172.12
-7,972.29
- -
- -
- -
-8,584.43
- -
- -
- -
- -
- -
- -
- -
Working Capital
2
6
3
2
2
2
- -
- -
- -
2
- -
-3
-3
-5
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
2
9
6
4
4
4
2
1
2
4
1
-2
-2
-4
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Jul'20
Oct'20
Jan'20
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
22
22
22
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Jul'20
Oct'20
Jan'20
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
4
4
5
Payables & Accruals
4
4
4
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-35.86%
-48.28%
51.76%
Free Cash Flow
0.19%
6.14%
-58.01%
Net Income, GAAP
0.83%
3.27%
-44.73%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2018
- -
- -
- -
- -
- -
2019
- -
- -
- -
- -
- -
2020
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2018
-0.02
-0.11
-0.08
- -
-0.31
2019
-0.04
-0.02
-0.01
- -
-0.12
2020
-0.02
-0.02
-0.02
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2018
- -
- -
- -
- -
- -
2019
- -
- -
- -
- -
- -
2020
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Richard T. Ho
Sector
Healthcare
Industry
Biotechnology
Address
The Canadian Venture Building Toronto ON Canada M5C 1P1
IPO Date
Sep 28, 2009
Website
cotingapharma.com
Similar Companies
H-CYTE, Inc. (HCYT)
co.don AG (CNWK.DE)
LakeShore Biopharma Co., Ltd (LSBCF)
Pluri Inc. (PLUR.TA)
Stealth BioTherapeutics Corp (MITO)
Asep Medical Holdings Inc (ASEP.CN)
Business
Cotinga Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company that develops targeted therapies for cancer and other unmet medical needs using its proprietary artificial intelligence platform, CHEMSAS, which employs predictive computer models to identify small-molecule drug candidates from disease-specific discovery through preclinical testing. The company offers lead product candidate COTI-2, an oral small molecule with a p53-dependent mechanism that activates the tumor suppressor gene p53 mutated in over 50% of cancers, demonstrating selective anti-cancer activity; COTI-219, an oral small molecule targeting mutant KRAS forms found in up to 30% of cancers without inhibiting normal KRAS function; and earlier-stage candidates including COTI-4A for small cell lung cancer and KRAS inhibitors, with the CHEMSAS platform applicable to any disease target. Founded in 2006 and headquartered in Toronto, Canada, with operations in Boston, Massachusetts, Cotinga focuses on oncology segments including pancreatic cancer, ovarian cancer, head and neck squamous cell carcinoma, gynecologic cancers, and triple negative metastatic breast cancer, targeting patients with high unmet needs through clinical trials at sites such as MD Anderson Cancer Center, Northwestern University Lurie Cancer Center, and St. Vincent’s University Hospital. Formerly known as Critical Outcome Technologies Inc., the company changed its name to Cotinga Pharmaceuticals Inc. in January 2018 to reflect its focus on targeted cancer therapies. Recent developments include a 2018 research collaboration with St. Vincent’s University Hospital to evaluate COTI-2 combined with eribulin for triple negative metastatic breast cancer; closure of a CAD $2.0 million private placement in May 2018 to fund Phase 1 expansion of COTI-2 in combination with standard-of-care chemotherapies across multiple cancers; and dosing of initial patients in combination therapy cohorts, with ongoing IND-enabling studies for COTI-219 and orphan drug designation for COTI-2 in ovarian cancer.